TY - JOUR T1 - Analyzing the effect of relaxing restriction on the COVID-19 outbreak for some US states JF - medRxiv DO - 10.1101/2021.04.19.21255759 SP - 2021.04.19.21255759 AU - Mahir Demir AU - ibrahim Halil Aslan AU - Suzanne Lenhart Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/20/2021.04.19.21255759.abstract N2 - The ongoing pandemic disease COVID-19 has caused worldwide social and financial disruption. As many countries are engaged in designing vaccines, the harmful second and third waves of COVID-19 have already appeared in many countries. To investigate changes in transmission rates and the effect of social distancing in the USA, we formulate a system of ordinary differential equations using data of confirmed cases and deaths in these states: California, Texas, Florida, Georgia, Illinois, Louisiana, Michigan, and Missouri in the USA to be able to investigate changes in transmission rates of the outbreak and effect of social distancing. Our models and the corresponding parameter estimations show social distancing reduces the transmission by 60% to 90%, and thus obeying the movement restriction rules plays a crucial rule to reduce the magnitudes of the outbreak waves. Our analysis shows the current management restrictions do not sufficiently slow the disease propagation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to acknowledge the generous support of the Turkish Ministry of National Education in the study, Batman University, University of Tennessee at Knoxville, and Michigan State University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWorld Health Organization New York Times https://www.who.int/ https://github.com/nytimes/covid-19-data ER -